2026 Sponsors

At BD Biosciences (BDB), we are committed to revolutionizing biopharma research with cutting-edge technologies. Our BD FACSDiscover™ Platform integrates spectral flow cytometry, real-time spatial information and image-enabled cell sorting, transforming immuno-oncology drug discovery. With innovations like BD CellView™ Image Technology and BD SpectralFX™ Technology, we enable high-throughput spectral immunophenotyping, revealing spatially distinct phenotypes. Our comprehensive solutions empower researchers to accelerate and de-risk next-generation cancer therapy development, supporting the scientific community from basic research to clinical applications.

Lytix Biopharma is a clinical-stage biotech company developing oncolytic molecule drugs for superficial and deep-seated tumors. Lytix's oncolytic approach has been clinically validated across multiple skin cancers, both as a
monotherapy and in combination with pembroluzumab and has the potential to redefine the standard of 
care for patients prior to surgery.

Picture Health develops interpretable, novel AI imaging biomarkers that characterize tumor biology from routine medical images. QVT™ is the first and only biomarker to directly measure tumor vascularity and angiogenesis from standard-of-care radiology available for all patients in active or completed clinical trials. Built on our Px™ Platform, these next-generation standard or custom radiomics and pathomics biomarkers enable biopharma partners to improve patient characterization, understand the mechanism-of-action, and accelerate decision-making through clinical trial deployment. early-phase oncology trials. For more information, please visit https://picturehealth.com/

Morgan Stanley is a leading global financial services firm offering investment banking, securities, wealth management, and investment management services to corporations, governments, institutions, and individuals worldwide, focusing on building, preserving, and managing wealth through core values like putting clients first and leading with exceptional ideas. They provide services from M&A advisory and capital markets to trading, research, and personalized wealth planning, operating in over 40 countries.  Morgan Stanley’s core values include do the right thing, put clients first, lead with exceptional ideas, commit to diversity & inclusion, and give back.

For more information please visit https://www.morganstanley.com/

Alloy Therapeutics is a biotechnology ecosystem company advancing drug discovery and development through AI-powered platforms and scientific expertise. Through collaborative partnerships, Alloy provides technologies and company-creation capabilities across multiple biologics modalities, integrating AI/ML, proprietary data, and human insight to reduce the time and cost of advancing programs to human data.

BeyondSpring is a clinical-stage biopharmaceutical company developing first-in-class therapies addressing high unmet medical needs. Its lead asset, Plinabulin, in late-stage clinical development for NSCLC and other indications, acts as a dendritic cell maturation agent that supports both anti-cancer activity and immune modulation to resensitizing tumors resistant to checkpoint inhibitors.

Coherus Oncology is focused on developing and commercializing a diversified portfolio of next-generation immuno-oncology therapies that potentially extend patient survival across tumor types. The approval of LOQTORZI® (toripalimab-tpzi) and the advancement of multiple clinical stage immuno-oncology candidates targeting the tumor microenvironment underscore our commitment to immuno-oncology as a means for providing better treatment outcomes for patients.

Immunai's engineering-first platform maps the immune system to enable the discovery and augmentation of novel therapeutics through single-cell sequencing, functional genomics, big data, and machine learning. Immunai has a strong track record of partnering with leading pharmaceutical and biotech companies, academic institutions, and hospitals to optimize preclinical and clinical decision-making.

To learn more, please visit https://www.immunai.com/.

Lumanity is a global strategic partner for biopharmaceutical companies, engineering breakthrough value to transform lives. With 1,200 experts conducting work in over 50 countries, we combine scientific, clinical, regulatory, and commercial expertise with advanced technology to accelerate and optimize access to life-changing medicines. To learn more, please visit https://lumanity.com/

Onc.AI develops clinically validated, rigorously engineered deep-learning imaging biomarkers that predict treatment response and survival across immuno-oncology therapies. Global biopharma partners use Onc.AI’s patented models to strengthen early-phase decision-making and complement traditional imaging endpoints when assessing whether to advance or discontinue immuno-oncology programs.

Ozette transforms how scientists surface cytometry insights through our cloud native, vertically integrated analytical platform and our high-dimensional cytometry assays via Ozette Lab. Built for reproducibility, our platform accelerates biomarker identification and drug development, providing fast, transparent analyses that move teams from raw data to confident decisions with greater efficiency.

For more information, please visit: https://www.ozette.com/biological-insights/

Scimega, a niche oncology CRO, attracts cutting-edge cancer trials to Canada with 50% quicker site start-up times for mid-size & smaller biopharma companies within the context of global clinical programs. Scimega’s team of oncology experts provide robust, Lean methodology and processes, and real-time feasibility data that keeps every trial this CRO monitors on a Lean trajectory. 

To learn more about the Canadian opportunity with Scimega, please visit: https://scimega.com

TD2 Oncology is a global, science-driven CRO offering integrated preclinical, regulatory, and clinical services for oncology drug development. From IND strategy to global trial execution, we accelerate complex programs by reducing risk, streamlining timelines, and delivering specialized support from early development through approval.

Yunu is redefining how imaging powers clinical research. The company’s intelligent, end-to-end workflow platform streamlines every stage of imaging-based trials—from image capture and reader assignment to adjudication and data export—ensuring scientific integrity and operational efficiency. Trusted by life sciences, pharmaceutical, cancer centers, and research organizations worldwide, Yunu empowers teams to manage complex imaging studies with clarity, confidence, and speed.

ACROBiosystems Group, founded in 2010 and listed in 2021, is a biotechnology company dedicated to advancing global biopharmaceutical and healthcare innovation. Its brands include Resilient Supply, CytoPak, SAFENSURE, FLAG, Star Staining, Aneuro, ComboX, and GENPower, offering recombinant proteins, kits, antibodies, and scientific services.

Biocytogen is a global biotech company advancing antibody drug discovery through innovative platforms. Via RenBiologics™, it provides fully human antibody modalities across 1,000+ targets. Through BioMice™, Biocytogen offers 4,000+ humanized models, integrated in vivo, ex vivo, and in vitro pharmacology, and custom gene-editing services.

ZEISS Microscopy empowers Biotech and Pharma industries with innovative imaging and workflow solutions for Tissue Multiplexing, 3D Human Tissue Models, and advanced Regulatory and Compliance workflow integration. Leveraging over 175 years of excellence in the fields of optics and optoelectronics, ZEISS combines cutting-edge microscopy solutions with expert Professional Services to enable accelerated discoveries, reproducible results, and regulatory readiness, helping you advance therapies and improve patient outcomes with confidence.

The Flywheel medical imaging platform empowers healthcare innovation by streamlining imaging data management, automating research workflows and preparing data for AI development. Scalable by design, Flywheel gives you tools to securely aggregate, annotate, curate and analyze large amounts of imaging and video data, either within your organization or with collaborators across the world.

Median provides best-in-class central imaging services for oncology clinical trials, enabling biopharmaceutical companies to accelerate life-saving cancer treatments with unmatched operational excellence and reliability. We are also leading the way in leveraging AI/ML-powered imaging intelligence to deliver insights that advance sponsors’ oncology programs worldwide.

MERIT is an oncology endpoint expert delivering image collection, centralized reading, and data management services for clinical trials since 2012. Through innovative and proven technologies, alongside our intuitive, seamless workflows, our experienced staff bring over a decade of clinical endpoint expertise, ensuring the integrity of your trials. Learn more: https://meritcro.com/oncology/

NeoSome Life Sciences is a Preclinical Contract Research Organization, providing individualized services to support the drug discovery process from proof of concept studies through early-stage development. We provide both non-GLP in vivo and in vitro support in several research areas and are very experienced in Oncology. Our state-of-the-art facility, located in Billerica, Massachusetts, can house several animal species. NeoSome is AAALAC accredited, OLAW accredited, and USDA certified.

Nona Biosciences provides integrated solutions for antibody discovery and development. Using proprietary Harbour Mice® platforms that generate fully human H2L2 and HCAbs, we support diverse therapeutic formats. From immunization to IND-enabling services, our platforms and tailored solutions empower partners to move efficiently from idea to IND with flexibility and confidence. 

OCCAM Immune is a non-profit Academic Research Organization emerging from Mount Sinai Hospital that provides immune monitoring services for clinical trials. Its streamlined process, from contracting to data delivery, and its one-stop shop approach—from sample processing to assays and data analysis—bridge academic research excellence with industrial scalability. For more information, go to https://occam-immune.com/

PredxBio builds the translational engine that makes spatial and multi-omic biology actionable for drug development. Using advanced spatial analytics and AI, its SpaceIQ™ platform integrates rigorous tissue and data quality control with multi-omic analysis to deliver decision-grade insights and biomarkers. Proven across active industry programs, PredxBio enables immune-response and resistance analysis, patient stratification, and mechanism-of-action insight from discovery through clinical development.

RadMD is a global Imaging Clinical Research Organization (iCRO) providing comprehensive imaging services for clinical trials from Phase 1 to Phase 4 for pharmaceutical and biotech companies as well as CROs. Supporting sites in over 70 countries and a network of 300+ subspecialty-trained radiologists and imaging experts, RadMD delivers consistent, compliant and high-quality imaging solutions.  For more information, visit https://radmdimaging.com

Sino Biological is a global bioreagent and CRO provider specializing in recombinant proteins, antibodies, and nucleic acids. With ProVir®, the world’s largest viral reagent collection, and SignalChem Biotech’s kinase expertise, we support biologics, cell therapy, immunology, and infectious disease research. Our U.S.-produced Propure® line delivers high-quality, endotoxin-free proteins. With a U.S. office providing localized support, Sino Biological ensures innovative, high-quality solutions for global academic and industrial clients.

Teiko is an end-to-end cytometry provider with the mission to make cytometry simple, scalable, and reliable. TokuKit, our 3-step blood preservation kit, enables global blood collection for centralized processing—samples stable for 24+ months. We offer mass and spectral cytometry panels with interactive dashboards, built-in statistics, and publication-ready visualizations.

MedQIA, WorldCare Clinical, and DARC have come together to form Voiant, the industry’s leading clinical trial imaging solution provider with unparalleled scientific and clinical domain expertise. Voiant’s purpose-built AI-powered platform Voiant Hub integrates all aspects of clinical trial imaging, providing biopharmaceutical companies with high-speed delivery of quality clinical endpoint data.

Alithea’s technology combines high-sensitivity mass spectrometry with advanced bioinformatics and machine learning to reveal the full complexity of HLA-presented peptides — enabling safer, more effective drug development. From tumor profiling to target validation and toxicity prediction, we turn deep biology into actionable insight. HLA-Compass is Alithea’s web-accessible HLA peptide database with >4800 samples from tumors and healthy tissues identifying clinically actionable insights for patient treatment.

Beacon accelerates decisions at every stage of the drug development journey through unparalleled data, insights, analytics and workflow solutions. Providing accurate and comprehensive drug (preclinical and clinical), trial, and commercial data for advanced modalities and complex disease areas.

Join 24/25 top Pharma companies who use Beacon to Make Faster, Better Drug Development Decisions.

BobcatBio is a clinical-stage, venture-backed biotech company that is pioneering novel Macrophage Driven Immunotherapy for the treatment of solid tumors and lymphomas.

GenoBioTX develops advanced genetically engineered animal models, offering 15,000+ catalog strains, 1,000+ humanized models along with 19,000+ custom models for drug discovery. GenoBioTX also provides pre-clinical CRO and fully human antibody development services across multiple disease areas, with a focus on immuno-oncology. For more information, visit genobiotx.com.

Immatics is committed to making a meaningful impact on the lives of patients with cancer. We are the global leader in precision targeting of PRAME, a target expressed in more than 50 cancers. Our cutting-edge science and robust clinical pipeline form the broadest PRAME franchise with the most PRAME indications and modalities, spanning TCR T-cell therapies and TCR bispecifics.

OrgaNova TRiCBIO provides patient-derived organoids with immune and TME preservation for predictive immuno-oncology drug discovery and development, offering services and collaborations to pharma and biotech.

radiomics.bio is an AI-powered medical imaging and advanced statistics clinical research organisation, optimising the development of new oncology treatments. radiomics.bio supports biotech and pharma companies in all stages of clinical development offering services including disease characterization, dose impact quantification, response evaluation, image biomarker identification and outcome predictions. With radiomics.bio you can quantify response for objective decision making, obtain early insights from clinical trials, explore and validate drug mechanisms of action, and increase your understanding of disease on a patient, organ, or lesion level for insight-based decision making. For more information, go to www.radiomics.bio

RareCyte provides Precision Biology™ products and services for discovery, translational research and clinical diagnostics. The Orion™ spatial biology platform enables whole-slide highly multiplexed tissue analysis for multiple samples per day. Comprehensive liquid biopsy offerings enable CTC and other rare cell characterization and single cell retrieval for molecular analysis and CDx development. For more information, go to https://rarecyte.com/

RoukenBio - Immunology CRO redefined.

We provide discovery to IND-enabling assay services in the therapeutic areas of inflammation,

autoimmunity, immuno-oncology, oncology and beyond.

7 Hills Pharma’s proven management team is advancing first-in-class selective integrin activators leveraging a unique MoA to improve cancer immunotherapy efficacy without increasing side effects.

Abalos is a clinical stage company. We develop a truly novel approach to overcome cancer immunotherapy hurdles based on a multi-modal mechanism of action.

Liberate Bio merges real in vivo biology with AI to design next-generation nanoparticles that selectively reprogram immune and other cell types—expanding genetic medicine far beyond the liver.

Lokon Pharma is a Swedish biotech focusing on the development of tumor microenvironment (TME) gene engineering viral vectors. The goal is to reprogram the immunosuppressive TME to initiate immunostimulatory signaling. The inserted genes are selected to provide in vivo activation and expansion of tumor-reactive T cells. The first product in clinical development is LOAd703 that was awarded Fast Track Designation by the FDA for the treatment of pancreatic cancer. A pivotal Phase 2/3 trial is underway.

OncoPrecision is a next-generation oncology therapeutics company leveraging large-scale, patient-derived biology and AI-enhanced discovery platforms to develop precision medicines with higher probability of clinical success.

Vizenpistat (SR-8541!A), a new revolutionary cancer therapy, is a first checkpoint inhibitor for innate immunity restoration, needed in ½ of all cancers, in Ph2 clinicals.

Syenex is an open-science genetic medicines delivery company. Using synthetic biology, we design and license plug-and-play delivery platforms with best-in-class specificity, scalability, and safety. Our flagship platform, VivoCell™, enables in vivo T cell delivery of genetic cargo. Founded in 2022, Syenex has built a portfolio of cell-specific ex vivo and in vivo platforms and 50+ partnerships across biopharma and academia.

TATUM Bioscience is redefining cancer treatment with multi-specific nanofilament immunotherapy. Our breakthrough technology boosts tumor visibility, restores immune function, and drives lasting antitumor responses—positioning TATUM at the forefront of next-generation immuno-oncology.

Virogin Biotech is a clinical-stage immuno-oncology company, with a primary focus on innovative HSV-1 based oncolytic virus (OV) and mRNA-based (including self-amplifying RNA/saRNA) therapeutics to elicit robust and durable anti-tumor immune response against solid tumors. Both the platforms exhibit a high degree of complementarity via a mechanism of heterologous prime-boost. Enhanced anti-tumor efficacy has been observed if OV and mRNA tumor vaccines were combined due to (1) modulation of immune-suppressive tumor microenvironment through release of immunological payloads carried by OV, and (2) antigen spread via direct tumor cell lysis triggered by OV infection, which functions like an in situ personalized tumor vaccine. Yet each platform has ‘plug-to-play' features to independently develop novel therapies against cancer & other indications. Our oncolytic HSV-1 platform has two candidates in clinical trials, with our most advanced asset in Phase 2. Candidates from our mRNA platform have also completed preclinical proof of concept.